IRVINE, Calif.--(EON: Enhanced Online News)--Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against Egalet Corporation (“Egalet” or the “Company”) (Nasdaq: EGLT). Investors who purchased or otherwise acquired Egalet shares between December 15, 2015, and January 9, 2017, inclusive (the “Class Period”), are encouraged to contact the firm in advance of the March 28, 2017 lead plaintiff deadline.
“no other single-entity extended-release morphine product submitted in an abbreviated new drug application or 505(b)(2) application can be approved for that use at this time.”
If you purchased shares of Egalet during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at email@example.com.
On January 9, 2017, Egalet released a statement concerning approval for its product Arymo ER. The same day, the U.S. Federal Drug Administration stated that a competitor product MorphaBond “has marketing exclusivity for labeling describing the expected reduction of abuse of single-entity extended-release morphine by the intranasal route due to physicochemical properties.” Because of MorphaBond’s exclusivity within this market, “no other single-entity extended-release morphine product submitted in an abbreviated new drug application or 505(b)(2) application can be approved for that use at this time.” When this information was revealed to the investing public, the value of Egalet stock fell, causing investors harm.
There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
If you wish to learn more about this lawsuit at no charge, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at firstname.lastname@example.org.
This press release may constitute Attorney Advertising in some jurisdictions.